Glibenclamide News and Research

RSS

Glibenclamide is an anti-diabetic drug in a class of medications known as sulfonylureas.

Anti-diabetic drug could be repurposed for treating Parkinson's disease

A hallmark of Parkinson's disease is the degeneration of a group of dopaminergic neurons in the brain, which play key roles in movement initiation and co-ordination.

24 Nov 2020

Metformin for diabetics with renal damage scores over Sulphonylureas in terms of heart safety

There are several drugs that are being used for treatment of type 2 diabetes. Many type 2 diabetics suffer from kidney disorders that are caused by persistent high levels of blood sugar.

25 Sep 2019

Risk of hypoglycemia differs between SU agents, study reveals

Adding sulphonylureas (SUs) to metformin remains a commonly used strategy for treating type 2 diabetes, but individual SUs differ and may confer different risks of abnormally low blood sugar, or hypoglycemia. SUs-which include newer generation agents such as gliclazide, glipizide, glimepiride, and glibenclamide-stimulate the production of insulin in the pancreas and increase the effectiveness of insulin in the body.

20 Jul 2016

Innovative treatment may help prevent brain swelling, death in stroke patients

New research has provided more evidence that an innovative treatment strategy may help prevent brain swelling and death in stroke patients. J. Marc Simard, professor of neurosurgery at the University of Maryland School of Medicine, along with colleagues at Yale University and Massachusetts General Hospital, found that Cirara, an investigational drug, powerfully reduced brain swelling and death in patients who had suffered a type of large stroke called malignant infarction, which normally carries a high mortality rate.

19 Mar 2016

A new approach to TBI therapy

Innovative angles of attack in research that focus on how the human brain protects and repairs itself will help develop treatments for one of the most common, costly, deadly and scientifically frustrating medical conditions worldwide: traumatic brain injury.

24 Mar 2015

IQWiG dossier assessment finds no added benefit of lixisenatide

Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.

3 Aug 2013

No added benefit from linagliptin in patients with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. The assessment of the new dossier according to the German Act on the Reform of the Market for Medicinal Products (AMNOG) again showed that no added benefit of the drug over the appropriate comparator therapy (ACT) can be determined, because the pharmaceutical company has not submitted any relevant studies.

31 Jan 2013

Metabolic stress can increase onset of atrial fibrillation

Researchers have found new evidence that metabolic stress can increase the onset of atrial arrhythmias, such as atrial fibrillation (AF), a common heart condition that causes an irregular and often abnormally fast heart rate.

9 Jan 2013

Study examines role of NLRP3 inflammasome in ventilator-induced lung injury

Mechanical ventilation is often lifesaving, but can also initiate or aggravate lung injury. A new study in the May issue of Anesthesiology examined the role of one particular receptor in the inflammatory pathway, the NLRP3 inflammasome, and whether it impacts ventilator-induced lung injury.

26 Apr 2012

Linagliptin does not offer added benefit for adults with type 2 diabetes

Linagliptin has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes mellitus whose elevated blood glucose levels are inadequately controlled by diet and exercise.

7 Jan 2012

Patients with type 2 diabetes can benefit from metformin than other drugs

New research suggests that several commonly prescribed drugs for type 2 diabetes may not be as effective at preventing death and cardiovascular diseases, such as heart attacks and stroke, as the oral anti-diabetic drug, metformin.

7 Apr 2011

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009